US 12,383,609 B2
Plasmodium sporozoite NPDP peptides as vaccine and target novel malaria vaccines and antibodies binding to
Antonio Lanzavecchia, Porza (CH); Joshua Hoong Yu Tan, Shah Alam (MY); Claudia Daubenberger, Mülheim (DE); and Brandon Wilder, Seattle, WA (US)
Assigned to Institute for Research in Biomedicine, Bellinzona (CH); Seattle Children's Hospital, Seattle, WA (US); and Schweizerisches Tropen-und Public Health-Institut, Basel (CH)
Appl. No. 16/606,207
Filed by INSTITUTE FOR RESEARCH IN BIOMEDICINE, Bellinzona (CH); SEATTLE CHILDREN'S HOSPITAL, Seattle, WA (US); and SCHWEIZERISCHES TROPEN—UND PUBLIC HEALTH-INSTITUT, Basel (CH)
PCT Filed Apr. 19, 2018, PCT No. PCT/EP2018/060113
§ 371(c)(1), (2) Date Oct. 17, 2019,
PCT Pub. No. WO2018/193063, PCT Pub. Date Oct. 25, 2018.
Claims priority of provisional application 62/487,266, filed on Apr. 19, 2017.
Prior Publication US 2020/0093909 A1, Mar. 26, 2020
Int. Cl. A61K 39/015 (2006.01); A61K 39/00 (2006.01); A61P 33/06 (2006.01); C07K 16/20 (2006.01)
CPC A61K 39/015 (2013.01) [A61P 33/06 (2018.01); C07K 16/205 (2013.01); A61K 2039/505 (2013.01)] 21 Claims
 
1. A recombinant nucleic acid molecule comprising:
(i) a polynucleotide encoding an antibody, or an antigen-binding fragment thereof, that is capable of binding to a Plasmodium falciparum sporozoite, wherein the antibody, or the antigen-binding fragment thereof, comprises:
a heavy chain variable region (VH) comprising a CDRH1, a CDRH2, and a CDRH3, the heavy chain variable region (VH) having an amino acid sequence, the amino acid sequence consisting of SEQ ID NO: 248;
a light chain variable region (VL) comprising a CDRL1, a CDRL2, and a CDRL3, the light chain variable region (VL) having an amino acid sequence, the amino acid sequence consisting of SEQ ID NO: 249;
an IgG1 Fc moiety comprising:
a heavy chain amino acid sequence, wherein the heavy chain amino acid sequence is according to SEQ ID NO: 313; and
a light chain amino acid sequence, wherein the light chain amino acid sequence is according to SEQ ID NO: 314 or 315; and
(ii) a promoter sequence.